keyword
MENU ▼
Read by QxMD icon Read
search

Novel treatments prostate

keyword
https://www.readbyqxmd.com/read/28918178/using-imaging-to-predict-treatment-response-in-genitourinary-malignancies
#1
REVIEW
Amir H Lebastchi, Matthew J Watson, Christopher M Russell, Arvin K George, Alon Z Weizer, Baris Turkbey
CONTEXT: Over the previous2 decades, there have been numerous advancements in the diagnostic evaluation, therapeutic management, and postoperative assessment of genitourinary malignancies. OBJECTIVE: To present a review of current and novel imaging modalities and their utility in the assessment of therapeutic response in the systemic management of renal, testicular, and prostate cancers. EVIDENCE ACQUISITION: A PubMed/Medline search of the current published literature inclusive of prospective and retrospective original research, systematic reviews, and meta-analyses was conducted evaluating imaging modalities for renal cell carcinoma, prostate cancer, and testicular cancer...
September 13, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28917266/urinary-biomarkers-in-prostate-cancer-detection-and-monitoring-progression
#2
REVIEW
Duojia Wu, Jie Ni, Julia Beretov, Paul Cozzi, Mark Willcox, Valerie Wasinger, Bradley Walsh, Peter Graham, Yong Li
Prostate cancer (CaP) is the most common cancer in men and the second leading cause of cancer deaths in males in Australia. Although serum prostate-specific antigen (PSA) has been the most widely used biomarker in CaP detection for decades, PSA screening has limitations such as low specificity and potential association with over-diagnosis. Current biomarkers used in the clinic are not useful for the early detection of CaP, or monitoring its progression, and have limited value in predicting response to treatment...
October 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28917257/exploiting-molecular-genomics-in-precision-radiation-oncology-a-marriage-of-biological-and-physical-precision
#3
Janice S H Tan, Xiaotian Lin, Kevin L M Chua, Paula Y Lam, Khee-Chee Soo, Melvin L K Chua
Achieving local tumour control is paramount for cure in head and neck and prostate cancers. With the transition to precision radiotherapy (RT) techniques, survival rates have improved in the majority of these cancers, but a substantial proportion of 30-40% still relapse following primary treatment. Recent large-scale molecular profiling studies have revealed unique biological events that could explain for tumour aggression and resistance to therapies, redefining the molecular taxonomy of head and neck and prostate cancers...
September 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/28915602/increased-expression-of-calponin-2-is-a-positive-prognostic-factor-in-pancreatic-ductal-adenocarcinoma
#4
Zhaoyan Qiu, Yi Chu, Bing Xu, Qian Wang, Mingzuo Jiang, Xiaowei Li, Gang Wang, Pengfei Yu, Guoxiao Liu, Hua Wang, Huijie Kang, Jiayu Liu, Yu Zhang, Jian-Ping Jin, Kaichun Wu, Jie Liang
Calponin 2 plays an important role in regulating actin cytoskeleton, which is critical for cell division and migration. Previous studies have demonstrated that calponin 2 inhibits prostate cancer cell proliferation and metastasis. However, the role of calponin 2 in pancreatic tumor growth, metastasis and patient survival remains unclear. Here, we demonstrate that the level of calponin 2 is a positive prognostic factor for patients with pancreatic ductal adenocarcinoma (PDAC). Patients with high calponin 2 expression in the tumor presented less lymph node metastasis and longer survival...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28915573/lipid-catabolism-inhibition-sensitizes-prostate-cancer-cells-to-antiandrogen-blockade
#5
Thomas W Flaig, Maren Salzmann-Sullivan, Lih-Jen Su, Zhiyong Zhang, Molishree Joshi, Miguel A Gijón, Jihye Kim, John J Arcaroli, Adrie Van Bokhoven, M Scott Lucia, Francisco G La Rosa, Isabel R Schlaepfer
Prostate cancer (PCa) is the most common malignancy among Western men and the second leading-cause of cancer related deaths. For men who develop metastatic castration resistant PCa (mCRPC), survival is limited, making the identification of novel therapies for mCRPC critical. We have found that deficient lipid oxidation via carnitine palmitoyltransferase (CPT1) results in decreased growth and invasion, underscoring the role of lipid oxidation to fuel PCa growth. Using immunohistochemistry we have found that the CPT1A isoform is abundant in PCa compared to benign tissue (n=39, p<0...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28910332/concurrent-treatment-with-simvastatin-and-nf-%C3%AE%C2%BAb-inhibitor-in-human-castration-resistant-prostate-cancer-cells-exerts-synergistic-anti-cancer-effects-via-control-of-the-nf-%C3%AE%C2%BAb-lin28-let-7-mirna-signaling-pathway
#6
Minyong Kang, Kyoung-Hwa Lee, Hye Sun Lee, Chang Wook Jeong, Ja Hyeon Ku, Hyeon Hoe Kim, Cheol Kwak
We examined the anti-cancer effects and molecular mechanism of simvastatin in human castration-resistant prostate cancer (CRPC) cells, particularly focused on LIN28B and its target molecule, let-7 microRNA (miRNA) among the various target genes of NF-κB. A human CRPC cell line (PC3) was used in the current study. Gene expression patterns were evaluated using real time-PCR and western blot analysis. CCK-8 assay was used for assessing cell viability and proliferation, and a clonogenic assay was adopted to evaluate clonal proliferative capabilities...
2017: PloS One
https://www.readbyqxmd.com/read/28905400/somatostatin-receptor-subtype-1-as-a-potential-diagnostic-marker-and-therapeutic-target-in-prostate-cancer
#7
Sergio Pedraza-Arévalo, Daniel Hormaechea-Agulla, Enrique Gómez-Gómez, María J Requena, Luke A Selth, Manuel D Gahete, Justo P Castaño, Raul M Luque
BACKGROUND: Prostate cancer (PCa) is a highly prevalent neoplasia that is strongly influenced by the endocrine system. Somatostatin (SST) and its five receptors (sst1-5 encoded by SSTR1-5 genes) comprise a pleiotropic system present in most endocrine-related cancers, some of which are successfully treated with SST analogs. Interestingly, it has been reported that SSTR1 is overexpressed in PCa, but its regulation, functional role, and clinical implications are still poorly known. METHODS: PCa specimens (n = 52) from biopsies and control prostates from cystoprostatectomies (n = 12), as well as in silico databases were used to evaluate SSTR1 and miRNAs expression...
September 14, 2017: Prostate
https://www.readbyqxmd.com/read/28904902/technique-considerations-and-complication-management-in-transurethral-resection-of-the-prostate-and-photoselective-vaporization-of-the-prostate
#8
REVIEW
Charles Welliver, Sevann Helo, Kevin T McVary
The prevalence of lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) increases with age. While a variety of treatments are available for these men, endoscopic treatments are generally preferred for men with small to moderate size glands. Novel treatment options are continually introduced into this large market. However, the practicing urologist should have a well tested surgical option in regular practice that is applicable to a wide range of patients. Herein we discuss two well recognized surgical options that can be used for the majority of men with LUTS due to BPH who have failed medical management...
August 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28904865/mouse-glutamate-carboxypeptidase%C3%A2-ii-gcpii-has-a-similar-enzyme-activity-and-inhibition-profile-but-a-different-tissue-distribution-to-human-gcpii
#9
Tomáš Knedlík, Barbora Vorlová, Václav Navrátil, Jan Tykvart, František Sedlák, Šimon Vaculín, Miloslav Franěk, Pavel Šácha, Jan Konvalinka
Glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA) or folate hydrolase, is a metallopeptidase expressed predominantly in the human brain and prostate. GCPII expression is considerably increased in prostate carcinoma, and the enzyme also participates in glutamate excitotoxicity in the brain. Therefore, GCPII represents an important diagnostic marker of prostate cancer progression and a putative target for the treatment of both prostate cancer and neuronal disorders associated with glutamate excitotoxicity...
September 2017: FEBS Open Bio
https://www.readbyqxmd.com/read/28903426/the-prognostic-implication-of-intraductal-carcinoma-of-the-prostate-in-metastatic-castration-resistant-prostate-cancer-and-its-potential-predictive-value-in-those-treated-with-docetaxel-or-abiraterone-as-first-line-therapy
#10
Jinge Zhao, Pengfei Shen, Guangxi Sun, Ni Chen, Jiandong Liu, Xin Tang, Rui Huang, Diming Cai, Jing Gong, Xingming Zhang, Zhibin Chen, Xiang Li, Qiang Wei, Peng Zhang, Zhenhua Liu, Jiyan Liu, Hao Zeng
Intraductal carcinoma of the prostate (IDC-P) is recognized as a newly pathological entity in 2016 WHO classification. It's role in metastatic castration-resistant prostate cancer (CRPC) remains obscure. We aimed to explore the association of IDC-P with clinical outcome and to further identify its potential predictive role in making first-line treatment decisions for mCRPC. We retrospectively analyzed data of 131 mCRPC patients. IDC-P was diagnosed by re-biopsy at the time of mCRPC. Among total patients, 45 and 41 received abiraterone or docetaxel as first-line therapies, respectively...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28903407/mir-331-3p-and-aurora-kinase-inhibitor-ii-co-treatment-suppresses-prostate-cancer-tumorigenesis-and-progression
#11
Michael R Epis, Keith M Giles, Dianne J Beveridge, Kirsty L Richardson, Patrick A Candy, Lisa M Stuart, Jacqueline Bentel, Ronald J Cohen, Peter J Leedman
RNA-based therapeutics could represent a new avenue of cancer treatment. miRNA 331-3p (miR-331-3p) is implicated in prostate cancer (PCa) as a putative tumor suppressor, but its functional activity and synergy with other anti-tumor agents is largely unknown. We found miR-331-3p expression in PCa tumors was significantly decreased compared to non-malignant matched tissue. Analysis of publicly available PCa gene expression data sets showed miR-331-3p expression negatively correlated with Gleason Score, tumor stage, lymph node involvement and PSA value, and was significantly down regulated in tumor tissue relative to normal prostate tissue...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28901516/two-novel-peptides-derived-from-sinonovacula%C3%A2-constricta-inhibit-the-proliferation-and-induce-apoptosis-of-human-prostate-cancer-cells
#12
Fangfang Huang, Guofang Ding, Zuisu Yang, Fangmiao Yu
In China, the incidence of prostate cancer has been increasing. Toxicity, drug resistance and limited transient benefits in patients are the main problems associated with standard chemotherapeutic regimens, and new drugs are therefore required to treat prostate cancer. SCH‑P9 and SCH‑P10 proteins were obtained from Sinonovacula constricta hydrolysates. The amino acid sequences of SCH‑P9 and SCH‑P10 were identified as Leu‑Pro‑Gly‑Pro and Asp‑Tyr‑Val‑Pro, with molecular weights of 382.46 Da and 492...
August 31, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28901490/targeting-strategies-of-adenovirus%C3%A2-mediated-gene-therapy-and-virotherapy-for-prostate-cancer-review
#13
Zhonglin Cai, Haidi Lv, Wenjuan Cao, Chuan Zhou, Qiangzhao Liu, Hui Li, Fenghai Zhou
Prostate cancer (PCa) poses a high risk to older men and it is the second most common type of male malignant tumor in western developed countries. Additionally, there is a lack of effective therapies for PCa at advanced stages. Novel treatment strategies such as adenovirus‑mediated gene therapy and virotherapy involve the expression of a specific therapeutic gene to induce death in cancer cells, however, wild‑type adenoviruses are also able to infect normal human cells, which leads to undesirable toxicity...
September 13, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28900507/targeting-micrornas-in-prostate-cancer-radiotherapy
#14
REVIEW
Jie Ni, Joseph Bucci, Lei Chang, David Malouf, Peter Graham, Yong Li
Radiotherapy is one of the most important treatment options for localized early-stage or advanced-stage prostate cancer (CaP). Radioresistance (relapse after radiotherapy) is a major challenge for the current radiotherapy. There is great interest in investigating mechanisms of radioresistance and developing novel treatment strategies to overcome radioresistance. MicroRNAs (miRNAs) are small, non-coding RNAs that regulate gene expression at the post-transcriptional level, participating in numerous physiological and pathological processes including cancer invasion, progression, metastasis and therapeutic resistance...
2017: Theranostics
https://www.readbyqxmd.com/read/28899970/targeting-prostate-cancer-subtype-1-by-forkhead-box-m1-pathway-inhibition
#15
Kirsi Ketola, Ravi Sn Munuganti, Alastair Davies, Ka Mun Nip, Jennifer L Bishop, Amina Zoubeidi
PURPOSE: Prostate cancer was recently classified to three clinically relevant subtypes (PCS) demarcated by unique pathway activation and clinical aggressiveness. In this preclinical study, we investigated molecular targets and therapeutics for PCS1, the most aggressive and lethal subtype with no treatment options available in the clinic. EXPERIMENTAL DESIGN: We utilized the PCS1 gene set and our model of enzalutamide (ENZR) castration-resistant prostate cancer (CRPC) to identify targetable pathways and inhibitors for PCS1...
September 12, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28895177/a-novel-use-for-olaparib-for-treatment-of-metastatic-castration-recurrent-prostate-cancer
#16
Grace A Martin, Adrienne H Chen, Kinjal Parikh
Although mortality from prostate cancer has declined over the past 20 years as a result of early detection and treatment, the 5-year survival rate for men with prostate cancer who develop metastatic disease is only 29%. Current treatment options for metastatic castration-recurrent prostate cancer (mCRPC) are associated with toxicity and a limited durable response; therefore, additional lines of efficacious and minimally toxic therapy are needed. Olaparib, a poly(adenosine 5'-diphosphate) ribose polymerase (PARP) inhibitor, received United States Food and Drug Administration breakthrough therapy designation in January 2016 for the treatment of patients with BRCA1/2 or ATM gene-mutated mCRPC based on results of a compelling phase II trial of olaparib in patients with advanced castration resistant prostate cancer (TOPARP-A)...
September 12, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28889753/silencing-of-bach1-inhibits-invasion-and-migration-of-prostate-cancer-cells-by-altering-metastasis-related-gene-expression
#17
Neda Shajari, Sadaf Davudian, Tohid Kazemi, Behzad Mansoori, Shima Salehi, Vahid Khaze Shahgoli, Dariush Shanehbandi, Ali Mohammadi, Pascal H G Duijf, Behzad Baradaran
BACKGROUND: Cancer lethality is mainly caused by metastasis. Therefore, understanding the nature of the genes involved in this process has become a priority. BACH1, a basic leucine zipper transcription factor, has been shown to transcriptionally regulate expression of a range of genes that are associated with breast cancer metastasis. However, the exact role and the underlying molecular mechanism of BACH1 in prostate cancer remain unclear. This study aims to explore the expression of BACH1 in prostate cancer tissues and the effect of BACH1 suppression on prostate cancer cell behavior...
September 11, 2017: Artificial Cells, Nanomedicine, and Biotechnology
https://www.readbyqxmd.com/read/28885207/effect-of-irreversible-electroporation-of%C3%A2-prostate-cancer-on-microcirculation-imaging-findings-in-contrast-enhanced-t1-weighted-3d-mri
#18
L P Beyer, B Pregler, N Verloh, K Brünn, M Haimerl, C Stroszczynski, E M Jung, P Wiggermann
OBJECTIVES: Irreversible electroporation (IRE) is a novel focal ablation technique applicable for treatment of prostate cancer (PCa). We aim to evaluate imaging findings of T1-weighted contrast-enhanced MRI after percutaneous IRE of low-risk PCa. METHODS: A total of 13 male patients underwent IRE of focal low-risk PCa and were included in this analysis. Prostate IRE was conducted using 2-4 electrodes being placed under CT-fluoroscopy guidance. Dynamic contrast-enhanced 3D isotropic fat-saturated T1-weighted MRI (DCE-MRI) was performed 24-72 hours before and 24-72 hours after ablation...
September 4, 2017: Clinical Hemorheology and Microcirculation
https://www.readbyqxmd.com/read/28880012/golph2-regulated-oncolytic-adenovirus-gd55-exerts-strong-killing-effect-on-human-prostate-cancer-stem-like-cells-in-vitro-and-in-vivo
#19
Chang Ying, Bo-Duan Xiao, Yun Qin, Bin-Rong Wang, Xin-Yuan Liu, Ru-Wei Wang, Ling Fang, Hui Yan, Xiu-Mei Zhou, Yi-Gang Wang
GOLPH2 (also called GP73) is a Golgi glycoprotein, which has been identified as a novel tumor marker upregulated in various cancers, including prostate cancer (PCa). GD55 is a novel GOLPH2-regulated oncolytic adenovirus that exhibits a strong killing effect on hepatoma cells. Here, we investigate the antitumor effect of GD55 on prostate cancer stem cell (CSC)-like cells in vitro and in vivo. Prostate CSC-like sphere cells were acquired and enriched by culturing DU145, LNCap or P3 prostate cancer cells in suspension...
September 7, 2017: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/28872453/allium-stents-a-novel-solution-for-the-management-of-upper-and-lower-urinary-tract-strictures
#20
Zaher Bahouth, Boaz Moskovitz, Sarel Halachmi, Ofer Nativ
Stents are widely use in endoscopic urological procedures. One of the most important indications is the treatment of urinary tract strictures. Allium(™) Medical has introduced several types of stents for the treatment of different types of urinary tract strictures, based on anatomic location. All the stents are made of nitinol and coated with a co-polymer that reduces encrustations. These stents are self-expandable and have a large caliber and a high radial force. They have different shapes, designed especially for the treatment of each type of stricture...
August 22, 2017: Rambam Maimonides Medical Journal
keyword
keyword
110082
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"